Andere Sprachen Duality Biotherapeutics, Inc.

Aktien

A414LZ

KYG2929M1087

9606

Pharmazeutika

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:30 11.06.2026			% 5 Tage	Veränd. 1. Jan.
179,10 ^HKD	+1,47 %		-10,54 %	-39,94 %

26.05.	Duality Biotherapeutics, Inc. (SEHK:9606) startet Aktienrückkaufprogramm über 8.803.626 Aktien bzw. 10 % des Grundkapitals auf Basis der Ermächtigung vom 20. Juni 2025.	CI
20.05.	Duality Biotherapeutics lanciert Aktienrückkaufprogramm über 40 Millionen Dollar; Aktie legt um 3% zu	MT

Andere Sprachen

26.05.	Duality Biotherapeutics, Inc. commences an Equity Buyback Plan for 8,803,626 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2025.
20.05.	Duality Biotherapeutics Launches $40 Million Stock Buyback; Shares Rise 3%
19.05.	Duality Biotherapeutics announces share repurchase plan of up to $40 million
13.04.	Duality Biotherapeutics approved proposed RMB share issue on sci-tech board
09.04.	DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
09.04.	DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
09.04.	Duality Biotherapeutics' Biologics License Application for Breast Cancer Drug Accepted in China
09.04.	Duality Biotherapeutics says NMPA accepts biologics license application for DB-1303/BNT323
24.03.	DualityBio (9606.HK) Announces 2025 Annual Results
24.03.	Duality Biotherapeutics' Loss Widens in 2025; Appoints CFO; Shares Lose 3%
23.03.	Duality Biotherapeutics FY revenue rmb1.85 billion
23.03.	Duality Biotherapeutics Inc says Si Wen tendered resignation as exec director
23.03.	Duality Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
23.03.	Duality Biotherapeutics, Inc. Announces Board and Committee Changes, with Effect from March 23, 2026
23.03.	Duality Biotherapeutics, Inc. Appoints ZHANG Shaoren as Chief Financial Officer, with Effect from March 23, 2026
24.02.	Duality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study
23.02.	Duality Biotherapeutics, Inc. Announces Update on Efficacy and Safety Results from Core Product Db-1311/Bnt324 At Asco Genitourinary Cancers 2026
20.10.25	Duality Biotherapeutics Board OKs Sci-Tech Board Listing on Shanghai Bourse; Shares Rise 5%
17.10.25	Duality Biotherapeutics proposes issue of RMB shares & listing on the Sci-Tech-Board of the Shanghai Stock Exchange
14.10.25	Certain Ordinary Shares of Duality Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-OCT-2025.
22.09.25	Duality Biotherapeutics, Inc.(SEHK:9606) added to S&P Global BMI Index
08.09.25	Duality Biotherapeutics to Join Hang Seng Index
05.09.25	Duality Biotherapeutics' Trial of Breast Cancer Drug Reaches Primary Endpoint
05.09.25	BioNTech, Duality score initial trial win with breast cancer precision drug
05.09.25	BioNTech, Duality score initial trial win with breast cancer precision drug